A Pilot Study on the Role of Autoantibody Targeting the β1-Adrenergic Receptor in the Response to β-blocker Therapy for Congestive Heart Failure

Journal of Cardiac Failure

Volumn 15, Issue 3, 2009, Pages 224-232

  Nagatomo, Yuji ^a   Yoshikawa, Tsutomu ^a   Kohno, Takashi ^a   Yoshizawa, Akihiro ^b   Baba, Akiyasu ^c   Anzai, Toshihisa ^a   Meguro, Tomomi ^d   Satoh, Toru ^a   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

^c KITASATO INSTITUTE HOSPITAL   (Japan)

^d TOKYO ELECTRIC POWER COMPANY   (Japan)

Author keywords

Autoantibody; carvedilol; dilated cardiomyopathy; metoprolol

Indexed keywords

AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICULOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; AUTOANTIBODIES; CARBAZOLES; DIASTOLE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART RATE; HEART VENTRICLES; HUMANS; MALE; METOPROLOL; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PILOT PROJECTS; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-1; STROKE VOLUME; SYSTOLE;

EID: 62649147901     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.10.027     Document Type: Article

References (34)

1. Magnusson Y., Marullo S., Hoyer S., Waagstein F., Andersson B., Vahlne A, Guillet J.G., Stroberg A.D., Hjalmarson A., and Hoebeke J. Mapping of a functional autoimmune epitope on the β1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 86 (1990) 1658-1663
2. Magnusson Y., Wallukat G., Waagstein F., Hjalmarson A., and Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation 89 (1994) 2760-2767
3. Magnusson Y., Hjalmarson A., and Hoebeke J. Beta1-adrenoceptor autoimmunity in cardiomyopathy. Int J Cardiol 54 (1996) 137-141
4. Jahns R., Boivin V., Siegmund C., Inselmann G., Lohse M.J., and Boege F. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99 (1999) 649-654
5. Iwata M., Yoshikawa T., Baba A., Anzai T., Mitamura H., and Ogawa S. Autoantibodies against the second extracellular loop of β1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 37 (2001) 418-424
6. Wallukat G., Wollenberger A., Morwinski R., and Pitschner H.F. Anti-β1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 27 (1995) 397-406
7. Mobini R., Magnusson Y., Wallukat G., Viguier M., Hjalmarson A., and Hoebeke J. Probing the immunological properties of the extracellular domains of the human β1-adrenoceptor. J Autoimmun 13 (1999) 179-186
8. Mobini R., Fu M., Wallukat G., Magnusson Y., Hjalmarson A., and Hoebeke J. A monoclonal antibody directed against an autoimmune epitope on the human beta1-adrenergic receptor recognized in idiopathic dilated cardiomyopathy. Hybridoma 19 (2000) 135-142
9. Staudt A., Mobini R., Fu M., Grosse Y., Stangl V., Stangl K., Thiele A., Baumann G., and Felix S.B. β1-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharm 423 (2001) 115-119
10. Podlowski S., Luther H.P., Morwinski R., Muller J., and Wallukat G. Agonistic anti-β1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the β1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation 98 (1998) 2470-2476
11. Jahns R., Boivin V., Krapf T., Wallukat G., Boege F., and Lohse M.J. Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol 36 (2000) 1280-1287
12. Iwata M., Yoshikawa T., Baba A., Anzai T., Nakamura I., Wainai Y., Takahashi T., and Ogawa S. Autoimmunity against the second extracellular loop of β1-adrenergic receptors induces β-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 88 (2001) 578-586
13. Staudt Y., Mobini R., Fu M., Felix S.B., Kuhn J.P., and Staudt A. β1-Adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharm 466 (2003) 1-6
14. Christ T., Wettwer E., Dobrev D., Adolph E., Knaut M., Wallukat G., and Ravens U. Autoantibodies against the β1-adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 33 (2001) 1515-1525
15. Jahns R., Boivin V., Hein L., Triebel S., Angermann C.E., Ertl G., and Lohse M.J. Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113 (2004) 1419-1429
16. Stork S., Boivin V., Horf R., Hein R., Lohse M.J., Angermann C.E., and Jahns R. Stimulating autoantibodies directed against the cardiac β1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 152 (2006) 697-704
17. Fukuda Y., Miyoshi S., Tanimoto K., Oota K., Fujikura K., Iwata M., Baba A., Hagiwara Y., Yoshikawa T., Mitamura H., and Ogawa S. Autoimmunity against the second extracellular loop of beta1-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol 43 (2004) 1090-1100
18. Wallukat G., Muller J., and Hetzer R. Specific removal of β1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347 (2002) 1806
19. The U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
20. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353 (1999) 9-13
21. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
22. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
23. Hori M., Sasayama S., Kitabatake A., Toyo-oka T., Handa S., Yokoyama M., Matsuzaki M., Takeshita A., Origawa H., Matsui K., and Hosoda S. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the multicenter carvedilol heart failure dose assessment (MUCHA) trial. Am Heart J 147 (2004) 324-330
24. Yokota Y., Nomura H., Kawai H., Tsumura Y., Takeuchi Y., Kurozumi H., Takarada A., and Fukuzaki H. Effects of long-term beta-blockade (metoprolol) therapy in patients with dilated cardiomyopathy. Jpn Circ J 55 (1991) 343-355
25. Kohno T., Yoshikawa T., Yoshizawa A., Nakamura I., Anzai T., Satoh T., and Ogawa S. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovasc Drugs Ther 19 (2005) 347-355
26. Miao G.B., Liu J.C., Liu M.B., Wu J.L., Zhang G., Chang J., and Zhang L. Autoantibody against β1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment. Eur J Clin Invest 36 (2006) 614-620
27. Bond R.A., Leff P., Johnson T.D., Milano C.A., Rockman H.A., McMinn T.R., Apparsundaram S., Hyek M.F., Kenakin T.P., Allen L.F., and Lefkowitz R.J. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature 374 (1995) 272-276
28. Mialet Perez J., Rathz D.A., Petrashevskaya N.N., Hahn H.S., Wagoner L.E., Schwartz A., Dorn G.W., and Liggett S.B. β1-Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9 (2003) 1300-1305
29. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., Weber S.A., Greene S.M., Hodne D., Nelson B., Morrison J., Domanski M.J., Wagoner L.E., Abraham W.T., Anderson J.L., Carlquist J.F., Krause-Steinrauf H.J., Lazzeroni L.C., Port J.D., Lavori P.W., and Bristow M.R. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
30. Rochais F., Vilardaga J.P., Nikolaev V.O., Bunemann M., Lohse M.J., and Engelhardt S. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 117 (2007) 229-235
31. Bristow M.R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., and Jamieson S. Beta1- and beta2-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium. Circ Res 59 (1986) 297-309
32. Communal C., Singh K., Sawyer D.B., and Colucci W.S. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis. Circulation 100 (1999) 2210-2212
33. Peter P.S., Brady J.E., Yan L., Chen W., Engelhardt S., Wang Y., Sadoshima J., Vatner S.F., and Vatner D.E. Inhibition of p38α MAPK rescues cardiomyopathy induced by oversexpressed β2-adrenergic receptor, but not β1-adrenergic receptor. J Clin Invest 117 (2007) 1335-1343
34. Liu H., Zhao R., Jiao X., Wang Y., and Fu M. Relationship of myocardial remodeling to the genesis of serum autoantibodies to cardiac beta1-adrenoceptors and muscarinic type 2 acetylcholine receptors in rats. J Am Coll Cardiol 39 (2002) 1866-1873